STOCK TITAN
  1. Home
  2. News
  3. IGMS

IGM Biosciences Inc - IGMS STOCK NEWS

Welcome to our dedicated news page for IGM Biosciences (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on IGM Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IGM Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IGM Biosciences's position in the market.

News
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Rhea-AI Summary
IGM Biosciences refocuses its collaboration with Sanofi on immunology/inflammation targets, retaining global rights to oncology targets. The agreement includes up to $1,065 million in milestone payments per target and royalties on global net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.63%
Tags
none
-
News
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Rhea-AI Summary
IGM Biosciences, Inc. (IGMS) CEO to participate in fireside chat at Stifel 2024 Virtual Targeted Oncology Forum. Webcast details available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.41%
Tags
conferences
-
News
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
IGM Biosciences, Inc. (IGMS) announces financial results for Q4 and full year 2023, highlighting progress in clinical development of lead product candidates. The company provides updates on aplitabart and imvotamab trials, with promising enrollment and data expectations. Financially, the company reports cash and investments of $337.7 million, collaboration revenues of $2.1 million, R&D expenses of $215.5 million, and a net loss of $246.4 million for 2023. IGM anticipates full year 2024 operating expenses of $210-$220 million and collaboration revenue of $3 million, aiming to maintain a cash balance of $180 million to support operations until Q2 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
earnings
News
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) announced that CEO Fred Schwarzer will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 8, 2024. The event will be webcast live and available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.17%
Tags
conferences
-
News
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. CEO Fred Schwarzer to discuss the company's progress in developing engineered IgM antibodies. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Medivir to present at the Carlsquare Equity Research Investor Day
Rhea-AI Summary
Medivir AB (MVIR) to present at Carlsquare Equity Research Investor Day, focusing on the latest developments and future plans, including a rights issue and the development program for fostrox with the aim of starting a pivotal phase 2b study in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
News
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
Rhea-AI Summary
IGM Biosciences, a clinical-stage biotechnology company (Nasdaq: IGMS), will focus on treating colorectal cancer using IgM death receptor 5 (DR5) agonist antibodies and autoimmune diseases using IgM T cell engager antibodies. The company plans to file an Investigational New Drug (IND) application for IGM-2644 (CD38 x CD3) to treat autoimmune diseases. All clinical development in hematologic oncology indications has been halted, and the company expects its cash runway to extend into the second quarter of 2026. A reduction in the workforce of approximately 22 percent is also expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
News
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
Rhea-AI Summary
Medivir AB (publ) (MVIR) held an extraordinary general meeting in Stockholm, adopting a resolution to approve a rights issue for new common shares with preferential rights for existing shareholders. The rights issue includes an issue of not more than 55,841,401 new common shares, increasing the Company's share capital by not more than SEK 27,920,700.50. The new shares are issued at a subscription price of SEK 2.65 per share, with a record date for participation in the new issue set for 5 December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.79%
Tags
none
-
News
Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC
Rhea-AI Summary
Medivir AB (MVIR) has developed an updated commercial formulation of fostrox, a potential treatment for hepatocellular carcinoma (HCC), a life-threatening form of liver cancer. The formulation was developed in collaboration with Quotient Sciences, the company's partner for formulation development and drug manufacture. Fostrox is currently being evaluated in a phase 1b/2a study in combination with Lenvima®, showing promising interim data for HCC patients who have progressed on current first-line standard of care. The company plans to initiate a phase 2b study with accelerated approval intent based on the positive results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none
News
Medivir to present at the Redeye Life Science Day
Rhea-AI Summary
Medivir AB (MVIR) to Participate at Redeye Life Science Day; CEO to Discuss Latest Developments and Future Plans
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
conferences
Stock IGMS logo
IGM Biosciences Inc

Nasdaq:IGMS

IGMS Rankings

#3045 Ranked by Market Cap
#5303 Ranked by Stock Gains
N/A Ranked by Dividends

IGMS Stock Data

538.49M
11.53M
35.23%
68.07%
8.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Mountain View

About IGMS

igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci